Lupin Delivers Beat in Q3; Nomura, Citi Raise Target Prices, Morgan Stanley Optimistic

delivered a better-than-expected performance in Q3 FY26, with strong traction in its US portfolio, expanded margins and regulatory progress cited by analysts. Following the results, several brokerages updated their outlooks: Nomura maintained a Buy rating with an increased target price, Citi raised its target price, and Morgan Stanley turned more optimistic, lifting its target while maintaining an equal-weight stance. Upgrades reflect confidence in Lupin’s earnings quality and growth drivers. What This Means * Analysts view Lupin’s US sales strength and margin visibility as key positive drivers. * Biosimilar approvals and pipeline progress are enhancing strategic growth prospects. * Upward revisions in target prices signal improved medium-term earnings expectations. Key Things to Watch Going Forward 1. **Sales momentum in the US generics and biosimilar segments. 2. Margin sustainability as product mix evolves. 3. Regulatory progress on new approvals and launches. 4. Investor confidence reflected in share price trends. Opinion Lupin’s Q3 performance and the subsequent positive commentary from multiple brokerages suggest that the company is navigating competitive and regulatory challenges effectively, especially in the important US market. Strong sales execution, margin improvement and progress on biosimilar approvals have boosted analyst confidence, leading to raised target prices. While near-term volatility in pharma pricing and regulatory risk remains, Lupin’s diversified portfolio and improving fundamentals could support earnings resilience and investor sentiment in the quarters ahead. Source: NDTV Profit No Recommendations